Internal Medicine, Hematology & Oncology · Hialeah, FL
NPI
1518256957
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
7150 W 20th Ave, Ste 214
Hialeah, FL, 33016
Phone (305) 826-8606
Groups this clinician bills Medicare through
Medicare paid, 2024
$591K
79,507 services
Medicare patients, 2024
138
Average age 76
Drug cost, 2024
$8.0M
2,388 prescriptions
Company payments, 2025
$1,788
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gustavo A Cadavid was code J1439 (injection, ferric carboxymaltose, 1 mg), 21,900 times for 13 patients. In total Gustavo A Cadavid billed 79,507 services in 62 codes, and Medicare paid $591K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-07-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 21,900 | 13 | $0.88 | $19K |
| 85025 Blood Count | Office | 435 | 88 | $7.51 | $3,269 |
| 36415 Venipuncture Blood Collection | Office | 346 | 86 | $8.53 | $2,950 |
| 96367 Intravenous Infusion, Hydration | Office | 258 | 12 | $23.59 | $6,087 |
| 96413 Chemotherapy Administration | Office | 154 | 17 | $109.44 | $17K |
| 99214 Office E&M - Established | Office | 135 | 87 | $101.18 | $14K |
| 96372 Injection Administration | Office | 121 | 14 | $12.21 | $1,477 |
| 99215 Office E&M - Established | Office | 96 | 46 | $146.22 | $14K |
| 96365 Intravenous Infusion, Hydration | Office | 93 | 27 | $54.02 | $5,024 |
| 99204 Office E&M - New | Office | 29 | 29 | $137.51 | $3,988 |
By year: 2022 $657K for 70,319 services; 2023 $549K for 75,056 services; 2024 $591K for 79,507 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 435 | 88 | $7.51 | $3,269 |
| 36415 Venipuncture Blood Collection | 346 | 86 | $8.53 | $2,950 |
Medicare prescription drug claims, 2024
In 2024, the drug Gustavo A Cadavid prescribed most often to Medicare patients was Anastrozole, with 459 prescriptions and refills. In total Gustavo A Cadavid wrote 2,388 Medicare prescriptions that cost $8.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 459 | 1,045 | 122 | $5,403 |
| Ondansetron Hcl Generic | 159 | 159 | 74 | $32K |
| Pantoprazole Sodium Generic | 124 | 172 | 44 | $585 |
| Xarelto Rivaroxaban | 120 | 122 | 26 | $68K |
| Eliquis Apixaban | 102 | 118 | 26 | $68K |
| Exemestane Generic | 101 | 143 | 14 | $19K |
| Lenalidomide Generic | 93 | 93 | 16 | $1.5M |
| Letrozole Generic | 69 | 143 | 22 | $1,397 |
| Lactulose Generic | 66 | 74 | 27 | $501 |
| Ibrance Palbociclib | 59 | 59 | Under 11 | $1.0M |
| Dexamethasone Generic | 54 | 54 | 20 | $462 |
| Erleada Apalutamide | 49 | 49 | Under 11 | $730K |
| Megestrol Acetate Generic | 48 | 52 | 21 | $1,524 |
| Hydroxyurea Generic | 48 | 86 | 17 | $901 |
| Revlimid Lenalidomide | 44 | 44 | 11 | $1.0M |
Brand drugs: - claims; generic drugs: 1,729 claims; opioid claims: 34.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gustavo A Cadavid $1,788 ($1,788 in general payments such as food, travel and fees) from 31 companies. The largest payer was Daiichi Sankyo Inc. with $267.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 7 | $267 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $191 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $133 |
| Genzyme Corporation SNY | 4 | $116 |
| Merck Sharp & Dohme LLC MRK | 4 | $88.57 |
| Janssen Biotech, Inc. JNJ | 3 | $78.57 |
| GlaxoSmithKline, LLC. GSK | 3 | $77.89 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $64.41 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $61.53 |
| Rigel Pharmaceuticals, Inc. RIGL | 2 | $61.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.